In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Sean W CutterCentre for Cardiovascular Biology and Disease Research, La Trobe Institute for Molecular Science (LIMS), La Trobe University, Melbourne, Victoria 3086, Australia.ORCID 0009-0009-7379-8029 Gang LiuSchool of Life Sciences, Faculty of Science, University Technology Sydney, Ultimo, New South Wales 2007, Australia.ORCID 0000-0002-0489-2638 Eleanor SaundersDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia.
Bailey CardwellDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria 3004, Australia.ORCID 0000-0003-4686-4210 Vinzenz HofferekDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia.
Thomas SoeriantoDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia.ORCID 0009-0005-0452-7074 Kaitlyn RitchieDepartment of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Victoria 3086, Australia.
Erin N S McGowanDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia.
Tien K NguyenDepartment of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Victoria 3086, Australia.ORCID 0000-0001-5224-2157 Ivan K H PoonDepartment of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Victoria 3086, Australia.ORCID 0000-0002-9119-7173 Malcolm J McConvilleDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia.ORCID 0000-0002-7107-7887 Benjamin J MarslandDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria 3004, Australia.
Glen P WestallDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria 3004, Australia.ORCID 0000-0002-3711-068X Mark D HulettDepartment of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Victoria 3086, Australia.ORCID 0000-0003-2072-5968 Nicholas P ReynoldsDepartment of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Victoria 3086, Australia.ORCID 0000-0003-4360-1335 Mark D WrightDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria 3004, Australia.ORCID 0000-0002-2177-5214 Philip M HansbroCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Camperdown, New South Wales 2050, Australia.ORCID 0000-0002-4741-3035 Katrina J BingerCentre for Cardiovascular Biology and Disease Research, La Trobe Institute for Molecular Science (LIMS), La Trobe University, Melbourne, Victoria 3086, Australia.ORCID 0000-0003-1139-3308 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Macrophages are key drivers of inflammatory and fibrotic diseases, and their activation is shaped by interactions in their tissue microenvironment. However, dissecting the processes that drive immunopathology has proved challenging, as traditional two-dimensional (2D) culture methods fail to capture the complex molecular environment that macrophages inhabit in vivo. To address this, we generated a 3D in vitro model to better mimic the in vivo biophysical microenvironment. We show that the extracellular matrix protein vitronectin promotes a previously unknown profibrotic macrophage phenotype in 3D that is characterized by increased expression of the nicotinamide adenine dinucleotide (NAD
Indexed as
Idiopathic Pulmonary FibrosisMacrophagesVitronectinAnimalsCell Culture TechniquesDisease Models, AnimalHumansMetabolic ReprogrammingMiceVitronectin
Identifiers
PMID42455923
PMCPMC13371895
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390